| Literature DB >> 21822474 |
Konstadina Griva1, Jan Stygall, Juan Hui Ng, Andrew Davenport, Mike J Harrison, Stanton Newman.
Abstract
Little is known on long-term outcomes in kidney transplantation. This study evaluated changes and predictors of generic and transplantation-specific health-related quality of life (HQoL) over six years in N = 102 kidney transplant survivors using the Short-form Health Survey-36 and the Transplant Effects questionnaire. Mixed models analysis was used to determine long-term outcomes. Emotional HQoL improved over time: Mental Component score, Mental Health, Energy (Ps = .000). Physical HQoL deteriorated: Physical Component Score (P = .001), Pain (P = .002). LRD transplant recipients had greater decline in physical functioning (P = .003) and PCS (P = .000) compared to cadaver recipients. Worry about the transplant (P = .036) and feelings of responsibility (P = .008) increased significantly over time. Worry about the transplant and perceived ability to work predicted 12.7% and 31.1% in variance in MCS and PCS, respectively. Efforts should be made to maintain HQoL and emotional outcomes with ongoing monitoring and support programs throughout the course of posttransplant care.Entities:
Year: 2011 PMID: 21822474 PMCID: PMC3142681 DOI: 10.1155/2011/671571
Source DB: PubMed Journal: J Transplant ISSN: 2090-0007
Figure 1Study cohort.
Sociodemographic and clinical characteristics of study sample.
| Total sample ( | Cadaver transplant ( | LRD transplant ( |
| |
|---|---|---|---|---|
|
|
|
| ||
| Age (years) | 46.57 (14.21) | 48.22 (14.67) | 40.43 (10.57) | .025 |
| Age (years) at diagnosis | 31.18 (16.99) | 32.81 (17.82) | 25.04 (11.85) | ns |
| Education (years) | 12.13 (4.46) | 11.87 (4.80) | 13.04 (2.94) | ns |
| Gender (% female) | 41.2% (42) | 39.5% (32) | 47.6% (10) | ns |
| Ethnicity (% white) | 76.5% (78) | 75.3% (61) | 81.0% (17) | ns |
| % married/cohabitating relationship | 62.7% (64) | 60.5% (49) | 71.4% (15) | ns |
| % employed (f/t; p/t) | 64.7% (66) | 60.5% (49) | 81.0% (17) | ns |
| % able to work | 76.5% (78) | 74.1% (60) | 85.7% (18) | ns |
|
| ||||
| Income | .012 | |||
|
| 16.7% (17) | 18.5% (15) | 9.5% (2) | |
|
| 24.5% (25) | 28.4% (23) | 9.5% (2) | |
|
| 15.7% (16) | 13.6% (11) | 23.8% (5) | |
| > | 21.6% (22) | 14.8% (12) | 47.6% (10) | ns |
|
| ||||
| % Diabetes | 6% (6) | 6.1% (5) | 4.7% (1) | ns |
| % Vascular disease | 21.5% (22) | 22.5% (18) | 19% (4) | ns |
| % Hypertension | 67.6% (69) | 67.9% (55) | 66.6% (14) | ns |
| GFR | 43.83 (20.47) | 43 (20.22) | 45.77 (22.14) | ns |
| Transplant vintage (years) | 8.08 (6.88) | 11.87 (4.80) | 11.25 (5.90) | .017 |
|
| ||||
| Primary kidney disease diagnosis (% yes) | ||||
| % GN | 14.7% (17) | 17.2% (14) | 14.3% (3) | |
| % APKD | 11.8% (12) | 12.3% (10) | 9.5% (2) | |
| % Reflux Nephropathy | 8.8% (9) | 9.8% (8) | 4.76 % (1) | |
| % Diabetes | 4.9% (5) | 6.2% (5) | 0% (0) | |
| % hypertension | 13.7% (14) | 16% (13) | 4.6% (1) | |
| % All Other | 44.1% (45) | 38.3% (31) | 66.6% (14) | |
RRT: renal replacement therapies; f/t: full time; p/t: part time; ESRD-SI: end-stage renal disease severity index; GFR: glomerular filtration rate; GN: glomerulonephritis; APKD: adult polycystic kidney disease.
† P values indicate significance of difference between CAD and LRD samples in the respective sociodemographic variables. ANOVA or Chi-square tests were used as appropriate.
Patient reported outcomes at baseline and 6-year followup: total transplant sample; Cadaver transplant and living related transplant recipients.
| CAD TX | LRD TX | Total Sample |
| ||||
|---|---|---|---|---|---|---|---|
| T1 | T2 | T1 | T2 | T1 | T2 | ||
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
|
| |||||||
| MCS | 45.84 (6.72) | 50.82 (11.05) | 43.50 (4.69) | 49.73 (8.35) | 45.30 (6.36) | 50.57 (10.45) | .000 |
| PCS | 44.93 (12.30) | 41.84 (12.29) | 51.40 (7.15) | 39.80 (14.70) | 46.41 (11.61) | 41.37 (12.80) | .001 |
| PF | 38.89 (16.91) | 38.55 (16.47) | 50.73 (6.21) | 41.46 (13.79) | 41.28 (16.06) | 39.14 (15.94) | ns |
| RPh | 45.88 (9.53) | 45.06 (10.37) | 51.14 (4.68) | 46.73 (8.83) | 46.94 (9.00) | 45.39 (10.05) | ns |
| Rem | 50.50 (6.88) | 48.36 (10.01) | 52.60 (4.17) | 50.56 (7.10) | 50.93 (6.45) | 48.81 (9.49) | .037 |
| SF | 40.14 (10.38) | 39.62 (14.65) | 45.90 (7.27) | 45.62 (11.24) | 41.34 (10.06) | 40.87 (14.17) | ns |
| MH | 41.65 (9.19) | 49.47 (12.59) | 42.44 (5.67) | 51.52 (9.36) | 41.84 (8.54) | 49.91 (11.96) | .000 |
| VT | 44.65 (7.18) | 48.97 (10.92) | 43.83 (6.09) | 45.86 (10.24) | 44.47 (6.94) | 48.30 (10.80) | .000 |
| BP | 48.11 (11.40) | 45.14 (13.15) | 52.89 (8.29) | 44.70 (13.91) | 49.11 (10.95) | 45.05 (13.24) | .002 |
| GH | 43.01 (11.55) | 41.29 (13.14) | 43.51 (10.04) | 39.54 (9.72) | 43.11 (11.21) | 40.94 (12.51) | ns |
|
| |||||||
|
| |||||||
| Worry | 3.03 (.88) | 3.25 (.71) | 3.07 (.87) | 3.30 (.77) | 3.04 (.87) | 3.26 (.72) | .036 |
| Guilt | 2.13 (.60) | 2.25 (.78) | 2.61 (.74) | 2.55 (.73) | 2.23 (.66) | 2.32 (.77) | ns |
| Disclos | 3.95 (.82) | 3.96 (.99) | 3.59 (1.15) | 4.05 (1.04) | 3.88 (.90) | 3.98 (.99) | ns |
| Adherence | 4.30 (.71) | 4.28 (.76) | 4.19 (1.11) | 4.00 (1.00) | 4.27 (.81) | 4.22 (.82) | ns |
| Responsibility | 3.72 (.71) | 3.97 (.85) | 3.71 (.74) | 3.96 (.76) | 3.72 (.71) | 3.97 (.83) | .008 |
CAD: cadaver; TX: transplant; LRD: living related donor; T1: baseline; T2: 6-year followup; GH: general health; PF: physical functioning; BP: bodily pain; VT: vitality; RPh: role limitations due to physical problems; REm: role limitations due to emotional problems; SF: social functioning; MH: mental health; MCS: mental component score; PCS: physical component scores; TXEQ: Transplant effects questionnaire; Disclos: disclosure.
†Normative based scoring: In all SF-36 sub-scales the general population mean is 50 and 10 is a standard deviation.
†† P value reported based on repeated measure ANOVAs conducted on total sample.
Figure 2Correlations between HQOL at followup (absolute scores) and sociodemographic, clinical, and psychological variables.
| PCS | MCS | PF | RPh | Rem | SF | MH | VT | BP | GH | |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |
| Age | −.312 (.007) | ns | −.468 (.000) | −.294 (.005) | ns | ns | ns | ns | ns | ns |
| Education (years) | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| Corrected GFR | ns | .434 (.038) | ns | ns | ns | ns | ns | ns | ns | Ns |
| Number of Comorbidities | −.408 (.000) | ns | −.424 (.000) | ns | ns | ns | ns | −.301 (.003) | −.220 (.031) | −.291 (.004) |
| Number of long-standing illness | −.422 (.000) | ns | −.439 (.000) | ns | ns | ns | ns | −.315 (.002) | ns | −.279 (.006) |
| Transplant vintage (years) | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
|
| ||||||||||
|
| ||||||||||
| Worry | ns | −.288 (.014) | ns | ns | ns | −.270 (.009) | −.299 (.003) | −.266 (.011) | ns | −.275 (.008) |
| Guilt | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| Disclosure | ns | ns | ns | ns | .243 (.024) | ns | ns | ns | ns | ns |
| Adherence | ns | .254 (.029) | ns | ns | ns | ns | ns | ns | ns | ns |
| Responsibility | −.312 (.007) | ns | −.376 (.000) | ns | ns | −.217 (.036) | ns | ns | ns | Ns |
TX: Transplant; GH: general health; PF: physical functioning; BP: bodily pain; VT: vitality; RPh: role limitations due to physical problems; REm: role limitations due to emotional problems; SF: social functioning; MH: mental health; MCS: mental component score; PCS: physical component scores; TXEQ: transplant effects questionnaire; Ns: nonsignificant correlations.